Summary
BeOne Medicines Ltd. (ONC) has filed its 2025 Annual Report with the Shanghai Stock Exchange's STAR Market, adhering to PRC accounting standards. This report, presented in Chinese, includes financial information for the year ended December 31, 2025, prepared in accordance with China Accounting Standards for Business Enterprises (CAS) and other PRC GAAP. Importantly, for U.S. investors, the Company has furnished supplementary financial information as an exhibit to this 8-K filing. This exhibit provides key metrics such as gross profit margin, R&D expenses broken down by product and project, and production/sales/inventory data for 2025, all prepared under U.S. GAAP. It also details the material differences between PRC GAAP and U.S. GAAP. This filing serves as a crucial update for investors, bridging the information gap between the primary Chinese filing and U.S. reporting requirements. Investors should pay close attention to Exhibit 99.1, which offers a U.S. GAAP perspective on the company's financial performance and operational metrics. The availability of this U.S. GAAP reconciled data is vital for a comprehensive understanding of BeOne Medicines' financial health and operational status for the 2025 fiscal year.
Key Highlights
- 1BeOne Medicines Ltd. filed its 2025 Annual Report with the Shanghai Stock Exchange STAR Market on April 14, 2026.
- 2The primary annual report is prepared in accordance with PRC GAAP and is available in Chinese.
- 3An exhibit (99.1) to the 8-K filing provides U.S. GAAP financial information for 2025.
- 4Exhibit 99.1 includes gross profit margin, R&D expenses by product/project, and production/sales/inventory data under U.S. GAAP.
- 5The filing also details material differences between PRC GAAP and U.S. GAAP.
- 6The furnished information in this 8-K is intended for U.S. investors to facilitate a U.S. GAAP understanding of the company's performance.